The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies
Official Title: An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Amivantamab, a Human Bispecific EGFR and cMet Antibody for the Treatment of Advanced Solid Malignancies
Study ID: NCT04606381
Brief Summary: The purpose of this study is to assess the feasibility of subcutaneous (SC) administration of amivantamab based on safety and pharmacokinetics and determine a dose, dose regimen and formulation for amivantamab SC delivery.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Cedars Sinai Medical Center, West Hollywood, California, United States
Community Health Network, Indianapolis, Indiana, United States
Langone Health at NYC University, NYU School of Medicine, New York, New York, United States
Providence Portland Medical Center, Portland, Oregon, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
University Health Network, Toronto, Ontario, Canada
Chungbuk National University Hospital, Cheongju-si, , Korea, Republic of
Seoul National University Bundang Hospital, Seongnam-si, , Korea, Republic of
Severance Hospital Yonsei University Health System, Seoul, , Korea, Republic of
Samsung Medical Center, Seoul, , Korea, Republic of
The Christie Nhs Foundation Trust, Manchester, , United Kingdom
Royal Marsden Hospital, Sutton, , United Kingdom
Name: Janssen Research & Development, LLC Clinical Trial
Affiliation: Janssen Research & Development, LLC
Role: STUDY_DIRECTOR